Antianaerobic activity of the ketolide RU 64004 compared to activities of four macrolides, five β-lactams, clindamycin, and metronidazole

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 5, 1997, Pages 1037-1041

  Ednie, L M ^a   Spangler, S K ^a   Jacobs, M R ^b   Appelbaum, P C ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CLARITHROMYCIN; CLAVULANIC ACID; CLINDAMYCIN; ERYTHROMYCIN; HMR 3004; MACROLIDE; METRONIDAZOLE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; ROXITHROMYCIN; TAZOBACTAM; UNCLASSIFIED DRUG;

ANAEROBIC BACTERIUM; ANAEROBIC INFECTION; ARTICLE; BACTEROIDES; CLOSTRIDIUM DIFFICILE; DRUG SENSITIVITY; FUSOBACTERIUM; MINIMUM INHIBITORY CONCENTRATION; PORPHYROMONAS; PREVOTELLA; PRIORITY JOURNAL;

EID: 0030945274     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.5.1037     Document Type: Article

References (20)

1. Agouridas, C., A. Bonnefoy, and J. F. Chantot. 1995. In vitro antibacterial activity of RU 004, a novel ketolide highly active against respiratory pathogens, abstr. F158, p. 140. In Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
2. Agouridas, C., A. Bonnefoy, and J. F. Chantot. 1995. Susceptibility testing conditions used and antibacterial activity of RU 004, abstr. F169, p. 142. In Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
3. Agouridas, C., A. Bonnefoy, and J. F. Chantot. 1995. In vivo antibacterial activity of RU 004, a novel ketolide highly active against respiratory pathogens, abstr. F171, p. 143. In Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
4. Barry, A. L., and P. C. Fuchs. 1991. Influence of the test medium on azithromycin and erythromycin regression statistics. Eur. J. Clin. Microbiol. Infect. Dis. 10:846-849.
5. Barry, A. L., and P. C. Fuchs. 1991. In-vitro potency of azithromycin against gram-negative bacilli is method-dependent. J. Antimicrob. Chemother. 28: 607-610.
6. Copeland, J. (Oxyrase, Inc.). 1995. Personal communication.
7. Dabernat, H., M. Seguy, and C. Delmas. 1995. In vitro activity of RU 004 against Haemophilus influenzae and Moraxella catarrhalis, abstr. F161, p. 141. In Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
8. Dubreuil, L. 1987. In-vitro comparison of roxithromycin and erythromycin against 900 anaerobic bacterial strains. J. Antimicrob. Chemother. 20(Suppl. B):13-19.
9. Fabre, R., J. D. Cavallo, J. C. Chapalain, and M. Meyran. 1995. Comparative in vitro activity of RU 004 against Neisseria gonorrhoeae and Neisseria meningitidis, abstr. F164, p. 141. In Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
10. George, W. L., B. D. Kirby, V. L. Sutter, D. M. Citron, and S. M. Finegold. 1981. Gram-negative anaerobic bacilli: their role in infection and patterns of susceptibility to antimicrobial agents. II. Little-known Fusobacterium species and miscellaneous genera. Rev. Infect. Dis. 3:599-626.
11. Hansen, S. L., P. Swomley, and G. Drusano. 1981. Effect of carbon dioxide and pH on susceptibility of Bacteriodes fragilis group to erythromycin. Antimicrob. Agents Chemother. 19:335-336.
12. Nachnani, S., E. Molitoris, and H. Wexler. 1992. In vitro activity of azithromycin against anaerobes using the microdilution technique with Oxyrase® supplemented broth, abstr. A-15, p. 3. In Abstracts of the 92nd General Meeting of the American Society for Microbiology 1992. American Society for Microbiology, Washington, D.C.
13. National Committee for Clinical Laboratory Standards. 1993. Methods for antimicrobial susceptibility testing of anaerobic bacteria, 3rd ed. Approved standard. NCCLS publication no. M11-A3. National Committee for Clinical Laboratory Standards, Villanova, Pa.
14. Ponticas, S., D. L. Shungu, and C. J. Gill. 1989. Evaluation of the Oxyrase™ membrane-bound enzyme system in broth media for susceptibility testing of anaerobic bacteria to imipenem, cefoxitin, and piperacillin, abstr. 878, p. 248. In Program and abstracts of the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
15. Pratt, K., and G. Hall. 1992. Oxyrase supplemented media for broth dilution MIC testing of anaerobes, abstr. C-366, p. 481. In Abstracts of the 92nd General Meeting of the American Society for Microbiology 1992. American Society for Microbiology, Washington, D.C.
16. Retsema, J. A., L. A. Brennan, and A. E. Girard. 1991. Significance of environmental factors on the in vitro potency of azithromycin. Eur. J. Clin. Microbiol. Infect. Dis. 10:834-842.
17. 2. J. Clin. Microbiol. 31:460-462.
18. 2 on susceptibilities of anaerobes to erythromycin, azithromycin, clarithromycin, and roxithromycin. Antimicrob. Agents Chemother. 38:211-216.
19. Spangler, S. K., M. R. Jacobs, and P. C. Appelbaum. 1995. Susceptibilities of 201 anaerobes to erythromycin, azithromycin, clarithromycin, and roxithromycin by Oxyrase agar dilution and E test methodologies. J. Clin. Microbiol. 33:1366-1367.
20. Summanen, P., E. J. Baron, D. M. Citron, C. A. Strong, H. M. Wexler, and S. M. Finegold. 1993. Wadsworth anaerobic bacteriology manual, 5th ed. Star Publishing Co., Belmont, Calif.